-
DE
Keytruda (pembrolizumab) is a cancer medication and immune checkpoint inhibitor that helps the immune system detect and destroy tumor cells.
Regular tips about health Regular tips about health Add as Preferred SourceKeytruda (pembrolizumab) is a cancer medication and immune checkpoint inhibitor that helps the immune system detect and destroy tumor cells.
Keytruda is the brand name for pembrolizumab, a monoclonal antibody classified as an immune checkpoint inhibitor. It is manufactured by MSD (Merck Sharp & Dohme) and is widely used in oncology. Keytruda has received approval from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for a broad range of cancer indications, making it one of the most widely approved cancer immunotherapies in the world.
The immune system uses checkpoints to prevent itself from attacking healthy tissue. Cancer cells exploit this mechanism by expressing a protein called PD-L1 (Programmed Death-Ligand 1) on their surface, which essentially makes them invisible to immune cells.
Pembrolizumab works by blocking the PD-1 (Programmed Cell Death Protein 1) receptor found on T-lymphocytes (immune cells). By blocking this receptor, the suppressive signal is removed, allowing T-cells to recognize and attack tumor cells once again.
Keytruda is approved for a wide range of cancers, including:
Keytruda is administered as an intravenous (IV) infusion, typically over 30 minutes. The standard dosing regimens are:
The exact dosage and treatment plan are determined individually by the treating oncologist based on the type and stage of cancer and the overall health of the patient. Treatment may continue for several months to years.
Because Keytruda activates the immune system, it can cause immune-related adverse events (irAEs), which can potentially affect almost any organ. Common side effects include:
Severe immune-related side effects require prompt medical management, usually with corticosteroids (e.g., prednisone) to suppress the excessive immune response. In some cases, treatment with Keytruda must be paused or permanently discontinued.
Not all patients respond equally well to Keytruda. A key predictive biomarker is PD-L1 expression in the tumor, which is measured from a tissue sample (biopsy). Higher PD-L1 expression generally correlates with a better response to treatment. Additional biomarkers such as tumor mutational burden (TMB) and microsatellite instability (MSI) can also guide patient selection.
Keytruda is frequently used in combination with other cancer treatments, including:
These combination approaches can enhance treatment efficacy but may also increase the risk of side effects, requiring close monitoring by the medical team.
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Average rating of 4.97 out of 5 stars
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
Average rating of 4.85 out of 5 stars
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
Average rating of 4.88 out of 5 stars
Daily basic supply: the complete spectrum of micronutrients
Natural multivitamin complex for the immune system, energy, and central body functions
Average rating of 4.94 out of 5 stars
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.